USC Norris Comprehensive Cancer Center to Collaborate with Trovagene to Standardize the Use of Trovera™ ctDNA Liquid Biopsy Tests in Patient Care
The USC Norris Comprehensive Cancer Center has entered into a new collaboration agreement with Trovagene, Inc., a San Diego-based developer of circulating tumor DNA (ctDNA) molecular diagnostics for cancer monitoring. This collaboration will seek to establish a standardized framework for using Trovagene’s Trovera™ urine liquid biopsy test in the clinic and define best practices for liquid biopsy testing from urine.
The academic-corporate collaboration was executed by the USC Stevens Center for Innovation, whose mission is to maximize the translation of USC research into products for public benefit through licensing, collaborations, and the promotion of entrepreneurship and innovation.
The collaboration with Trovagene will also explore the development of clinical treatment algorithms through investigational studies to solidify how and when liquid biopsy testing can be employed.
Liquid biopsy testing has been gaining traction in recent years as a less invasive alternative to traditional cancer screening methods.
“The clinical data Trovagene has presented and published thus far illustrate the tremendous promise of using urinary ctDNA as a noninvasive sample type to detect and monitor clinically actionable oncogene mutations, and provide essential molecular information about a patient’s disease,” said Stephen B. Gruber, M.D., Ph.D., M.P.H., director of the USC Norris Comprehensive Cancer Center, in a statement. “One of our key goals is to advance personalized medicine by investigating leading edge technologies, and provide clarity to the field for how and when these emerging technologies should be used. Ultimately, this pioneering work will facilitate new standards in patient care, and pave the way for new cancer treatment guidelines.”
“We look forward to working closely with clinicians and researchers at the USC Norris Comprehensive Cancer Center, a leader in cancer research, to further demonstrate the robustness and reliability of our technology in the identification of cancer mutations from urine,” said Mark Erlander, Ph.D., Chief Scientific Officer at Trovagene, in a statement. “Our collaboration is focused on conducting several novel studies that have potential to improve the standard-of-care for cancer treatment, and to accelerate adoption of our noninvasive tests into clinical practice.”
Trovagene is engaged in numerous collaborations with leading cancer centers and academic institutions, including a new collaboration announced earlier this month with the University of Michigan Comprehensive Cancer Center and, in 2015, a collaboration with University of California, San Diego’s Moores Cancer Center.
In 2013, USC and Trovagene implemented a clinical collaboration agreement surrounding colorectal cancer disease monitoring.
–by USC Stevens staff, published July 12, 2016